Carvedilol: A third-generation β-blocker should be a first-choice β-blocker

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 1, 2012, Pages 13-25

  DiNicolantonio, James J ^a   Hackam, Daniel G ^b  

^a Wegmans Pharmacy   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

atenolol; carvedilol; heart failure; hypertension; metoprolol; myocardial infarction

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; DRUG RECEPTOR BINDING; DRUG USE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; LIPOPHILICITY; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIOLOGICAL MARKERS; CARBAZOLES; HUMANS; HYPERTENSION; METOPROLOL; MYOCARDIAL INFARCTION; PROPANOLAMINES; RECURRENCE; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 83755172725     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.166     Document Type: Article

References (69)

1. Bristow MR, Ginsburg R, Umans V et al. β1-and β2-adrenergic- receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective b1-receptor down-regulation in heart failure. Circ. Res. 59, 297-309 (1986). (Pubitemid 17178124)
2. Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the b1-receptor? A perspective on the results of the COMET Trial. J. Card. Fail. 9, 429-443 (2003). (Pubitemid 38055650)
3. Forster C, Armstrong PW. Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. J. Cardiol. Pharmacol. 16, 708-718 (1990). (Pubitemid 20345252)
4. Hall JA, Kaumann AJ, Brown MJ. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ. Res. 66, 1610-1623 (1990). (Pubitemid 20178710)
5. Motomura S, Deighton NM, Zerkowski HR et al. Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2- muscarinic receptors in the human right atrium. Br. J. Pharmacol. 101, 363-369 (1990). (Pubitemid 20292891)
6. Xu XL, Zang WJ, Lu J et al. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton. Neurosci. 130, 6-16 (2006). (Pubitemid 44750853)
7. Du XJ, Autelitano DJ, Dilley RJ et al. β2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101, 71-77 (2000). (Pubitemid 30039079)
8. Grupp IL, Lorenz JN, Walsh RA et al. Overexpression of alpha1β-adrenergic receptor induces left ventricular dysfunction in the absenceof hypertrophy. Am. J. Physiol. 275, H1338-H1350 (1998).
9. Kaddoura S, Firth JD, Boheler KR et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93, 2068-2079 (1996).
10. Qin F, Rounds NK, Mao W et al. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovasc. Res. 51, 736-748 (2001). (Pubitemid 32800715)
11. Ohlstein EH, Arleth AJ, Storer B et al. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J. Mol. Cell. Cardiol. 30, 167-173 (1998). (Pubitemid 28069754)
12. Houle MS, Altschuld RA, Billman GE. Enhanced in vivo and in vitro contractile responses to beta(2)-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias. J. Appl. Physiol. 91, 1627-1637 (2001). (Pubitemid 32900353)
13. Lang CC, Rayos GH, Chomsky DB, Wood AJJ, Wilson JR. Effects of sympatho inhibition on exercise performance in heart failure. Circulation 96, 238-245 (1997). (Pubitemid 27298427)
14. Kindermann M, Maack C, Schaller S et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109, 3182-3190 (2004).
15. Pini R, Cavallini MC, Palmieri V et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano study. J. Am. Coll. Cardiol. 51, 2432-2439 (2008). (Pubitemid 351815169)
16. Polónia J, Barbosa L, Silva JA et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press. Monit. 15(5), 235-239 (2010).
17. The CAFÉ Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113, 1213-1225 (2006).
18. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J. Am. Coll. Cardiol. 54, 705-713 (2009).
19. Packer M, Antonopoulos GV, Berlin JA et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am. Heart J. 141, 899-907 (2001). (Pubitemid 32477000)
20. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 59, 539-544 (1998).
21. Cleland JG, Charlesworth A, Lubsen J et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality in patients with heart failure; a report from the Carvedilol or Metoprolol European Trial (COMET). J. Am. Coll. Cardiol. 47, 1603-1611 (2006).
22. Remme WJ, Cleland JG, Erhardt L et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur. J. Heart Fail. 9, 1128-1135 (2007). (Pubitemid 350011059)
23. Martsevich SY, Kutishenko NP, Deev AD et al. Comparison of antihypertensive and metabolic effects of carvedilol and metoprolol in hypertensive patients with overweight and obesity. J. Hypertens. 28, e560 (2010).
24. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. 126, 955-959 (1997). (Pubitemid 27255798)
25. Gilbert EM, Abraham WT, Olsen S. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94, 2817-2825 (1996). (Pubitemid 26411746)
26. Morimoto S, Shimizu K, Yamada K et al. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am. Heart J. 138, 456-459 (1999). (Pubitemid 29428767)
27. Lang CC, Rayos GH, Chomsky DB, Wood, AJJ, Wilson JR. Effects of sympatho inhibition on exercise performance in heart failure. Circulation 96, 238-245 (1997). (Pubitemid 27298427)
28. Marfella R, Ziniscalchi M, Nappo F et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertnesive patients. Am. J. Hypertens. 18, 308-318 (2005). (Pubitemid 40409909)
29. Hauf-Zachariou U, Wildmann L, Zulsdorf B et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur. J. Clin. Pharmacol. 45, 95-100 (1993). (Pubitemid 23267409)
30. Fonseca VA. Effect of β-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin. 26, 615-629 (2010).
31. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J. Am. Coll. Cardiol. 54, 705-713 (2009).
32. Frishman W, Henderson L, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc. Health Risk Manag. 4, 1387-1400 (2008).
33. McGill JB, Bakris GL, Fonseca V et al. Beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes. Obes. Metab. 9, 408-417 (2007). (Pubitemid 46502061)
34. Maisel AS, Peacock WF, McMullin N et al. Timing of immunoreactive β-type natriuretic peptide levels and treatment delay in acute decompensated heart failure. An ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J. Am. Coll. Cardiol. 52, 534-540 (2008).
35. Wannamethee SG, Welsh P, Lowe GD et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without preexisting cardiovascular disease. J. Am. Coll. Cardiol. 58, 56-64 (2011).
36. Chirinos JA, Zambrano JP, Chakko S et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 45, 980-985 (2005). (Pubitemid 40628947)
37. de Peuter OR, Lussan F, Peters RJG et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth. J. Med. 67, 284-294 (2009).
38. Carlberb B, Samuelsson O, Lindholm LH et al. Atenolol in hypertension: is it a wise choice? Lancet 364, 1684-1689 (2004).
39. Aurnes I, Osnes JB, Tvete IF, Gasemyr J Natvig B. Does atenolol differ from other βadrenergic blockers? BMC Clin. Pharmacol. 7, 4 (2007).
40. Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366, 1545-1553 (2005). (Pubitemid 41540112)
41. McAllister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150(11), 784-794 (2009).
42. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106, 2194-2199 (2002). (Pubitemid 35222212)
43. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357, 1385-1390 (2001). (Pubitemid 32455364)
44. Lopressor Intervention Trial Research Group. Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur. Heart J. 8, 1056-1064 (1987).
45. Jonsson G, Abdelnoor M, Muller C et al. A comparison of the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction: a single-centre, randomized study of 232 patients. Cardiology 103, 148-155 (2005). (Pubitemid 41094863)
46. Jonsson G, Abdelnoor M, Muller C et al. Effects of carvedilol compared to atenolol on ejection fraction and clinical endpoints after myocardial infarction. Eur. Heart J. 24, 555 (2003) (Abstract P2892).
47. Jonsson G, Abdelnoor M, Muller C et al. Effects of carvedilol compared to atenolol on ejection fraction and clinical endpoints after myocardial infarction. J. Am. Coll. Cardiol. 43(Suppl. A), 289A (2004) (Abstract 1118-1177).
48. Shen X, Nair CK, Aronow WS et al. Effect of carvedilol versus metoprolol CR/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: a COX multivariate regression analysis. Am. J. Ther. doi:10.1097/ MJT.0b013e3181f2abb3 (2011) (Epub ahead of print).
49. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362, 7-13 (2003). (Pubitemid 36835815)
50. Lopressor Intervention Trial Research Group. Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur. Heart J. 8, 1056-1064 (1987).
51. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2, 57-66 (1986).
52. Hjalmarson A, Herlitz J, Holmberg S et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67, I26-I32 (1983).
53. MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomized placebo-controlled international trial. Eur. Heart. J. 6, 199-226 (1985).
54. Roberts R, Rogers WJ, Mueller HS et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation 83, 422-437 (1991).
55. Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure; data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93, 968-973 (2007). (Pubitemid 47122050)
56. COMMIT collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet 366, 1622-1632 (2005).
57. Acikel S, Bozbas H, Gultekin B et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int. J. Cardiol. 135, 393-396 (2009).
58. Khamoushi AJ, Emkanjoo Z, Fazelifar AF et al. Optimal β-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 4, 1140-1174 (2007).
59. No authors listed. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
60. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349, 375-380 (1997).
61. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334, 1349-1355 (1996). (Pubitemid 26152713)
62. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90, 1765-1773 (1994).
63. No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353, 9-13 (1999).
64. Willenheimer R, van Veldhuisen DJ, Silke B et al.; on behalf of the CIBIS III investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112, 2426-2435 (2005). (Pubitemid 41504492)
65. Willenheimer R, Silke B. Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. Br. J. Cardiol. 12, 448-454 (2005). (Pubitemid 43023774)
66. Willenheimer R. The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial. Eur. Heart J. 11, A15-A20 (2009).
67. Flather MD, Shibata MC, Coats AJ et al.; on behalf of SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225 (2005). (Pubitemid 40222359)
68. Tolg R, Witt M, Schwarz B et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention - the PASSAT study. Clin. Res. Cardiol. 95, 31-41 (2006). (Pubitemid 43155313)
69. Basu S, Senior R, Raval U, Van Der Does R, Bruckner T, Lahiri A. Benefical effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo controlled randomized trial. Circulation 96, 183-191 (1997). (Pubitemid 27298420)